There are errors in the “Oncomine data analysis” section of the Materials and Methods. It should read:

Oncomine and CCLE data analysis

We used the Oncomine Cancer Genomics Data Analysis tool [30] and Cancer Cell Line Encyclopedia, CCLE [35] to mine Usmg5 copy number profiles in a large subset of cancer cell lines [31, 34, 35, 38, 41, 65–69]. In the dataset, the log2 (≥ 0,34) values were analyzed. The number of DNA copies (= 2*(2^y-axis value)) were calculated as advised in Oncomine instructions.

There are errors in the “Usmg5 copy number in cancers” section of the Results. It should read:

Usmg5 copy number in cancer cell lines

Since DAPIT over-expression induced EMT and glycolytic switch in HEK293T cells, we tested if DAPIT is over-presented in cancer cell lines. The Oncomine Cancer Genomics database and CCLE revealed a duplication (3–4 copies) of Usmg5 copy number in a large panel of cell lines (Table 2) Several datasets indicated uniform increase in copy number in various lung (NCI-H1775, NCI-H1993, NCI-H1563, NCI-H1755, VMRC-LCD, SBC-5, NCI-H1703), gastric (HCT116, Hs746T, MKN74, SNU-668), ovarian (OVTOKO, MCAS), liver (SNU-398) and pancreatic (PSN1, PANC-1) cancer cell lines. The copy number was also confirmed in breast (SUM-52PE), endometrial (AN3CA), esophagus (OE33), hematopoietic (MPLM6), kidney (SNU-1272) and lymphoid (Ki-JK) cell lines, being encountered once in the others. These data strongly suggest a role for DAPIT over-expression in cancers.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 2. Cancer cell lines expressing increased genomic Usmg5 copy number in Oncomine cancer genomics database and Cancer Cell Line Encyclopedia, CCLE.

https://doi.org/10.1371/journal.pone.0141036.t001

There are errors in Table 2 and in its caption. Please see the corrected Table 2 and its correct caption below.

There are errors in the last sentence in the penultimate paragraph of the Discussion. It should read: Interestingly, searching in the Oncomine cancer genomics database and Cancer Cell Line Encyclopedia, CCLE, revealed a duplication in Usmg5 copy number in various cancer cell lines (Table 2), highlighting several lung, gastric, ovarian, liver and pancreatic cancer cell lines by supporting fidelity in duplication. The copy number was also confirmed in some breast, endometrial, esophageal, hematopoietic, kidney and lymphoid cell lines. Despite the link between DAPIT and the tumorigenic capacity has not been sufficiently demonstrated, this result strengthens a correlative involvement of DAPIT in cancer and suggests a possible oncogenic function for it.

There are errors in the References. Please view the correct additional references, which are also corrected in Table 3 and the article text described above.

65. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Throne NPet al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007;8(10):R215. doi: 10.1186/gb-2007-8-10-r215

66. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009 Apr;7(4):511–22. doi: 10.1158/1541-7786.MCR-08-0107

67. Lu X, Zhang K, Van Sant C, Coon J, Semizarov D. An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. BMC Med Genomics. 2010 Jun 22;3:23. doi: 10.1186/1755-8794-3-23

68.Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res. 2007 Apr;5(4):331–9. Doi: 10.1158/1541-7786

69. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009; Jun;119(6):1727–40. doi: 10.1172/JCI37127